Kousaku Mimura
- Immunology top 2%
- Immune Cell Function and Interaction 21
- Immunotherapy and Immune Responses 14
- T-cell and B-cell Immunology 8
- Immune cells in cancer 4
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 16
- HER2/EGFR in Cancer Research 9
- CAR-T cell therapy research 5
-
- Monoclonal and Polyclonal Antibodies Research 10
- Cancer Research top 10%
Kousaku Mimura
48 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 94
- Immunology 1.3k
- Oncology 1.5k
- Radiology, Nuclear Medicine and Imaging 295
- Cancer Research 172
- Pulmonary and Respiratory Medicine 347
Countries citing papers authored by Kousaku Mimura
This map shows the geographic impact of Kousaku Mimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kousaku Mimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kousaku Mimura more than expected).
Fields of papers citing papers by Kousaku Mimura
This network shows the impact of papers produced by Kousaku Mimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kousaku Mimura. The network helps show where Kousaku Mimura may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kousaku Mimura, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 33 | |
| 2 | 2017 | 259 | |
| 3 | 2017 | 21 | |
| 4 | 2017 | 27 | |
| 5 | 2013 | 272 | |
| 6 | 2012 | 185 | |
| 7 | 2012 | 63 | |
| 8 | 2012 | 23 | |
| 9 | 2011 | 72 | |
| 10 | 2011 | 15 | |
| 11 | 2010 | 48 | |
| 12 | 2010 | 134 | |
| 13 | Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. | 2009 | 15 |
| 14 | 2008 | 86 | |
| 15 | Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. | 2007 | 52 |
| 16 | 2006 | 6 | |
| 17 | 2006 | 17 | |
| 18 | 2006 | 107 | |
| 19 | 2006 | 142 | |
| 20 | 2004 | 47 |
About Kousaku Mimura
Kousaku Mimura is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 49 papers that have together received 2.3k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (21 papers), Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), HER2/EGFR in Cancer Research (9 papers), T-cell and B-cell Immunology (8 papers), CAR-T cell therapy research (5 papers) and Immune cells in cancer (4 papers). The work is most often cited by research in Immunology (1.3k citations), Oncology (1.5k citations) and Radiology, Nuclear Medicine and Imaging (295 citations). Kousaku Mimura has collaborated with scholars based in Japan, Singapore and Sweden. Frequent co-authors include Koji Kono, Hideki Fujii, Yoshihiko Kawaguchi, Mitsuaki Watanabe, Takanori Maruyama, Hideki Fujii, Yoshiyuki Suzuki, Dario Campana, Noriko Shimasaki and Shinichirou Izawa. Their work appears in journals such as Cancer Immunology Immunotherapy, International Journal of Cancer, The Journal of Immunology, OncoImmunology and Cancer Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.